- Ab00726-23.0 Anti-CCR4 [KW-0761 (Mogamulizumab)]
- Rabbit IgG
- In Stock
- Ab00726-2.0 Anti-CCR4 [KW-0761 (Mogamulizumab)]
- Mouse IgG2a
- In Stock
Recombinant monoclonal antibody to CCR4. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody KW-0761 (Mogamulizumab).
UniProt Accession Number of Target Protein: P51679
Alternative Name(s) of Target: CD194; CKR-4; CCR-4; CCR4; K5-5
Immunogen: This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
Specificity: This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
Application Notes: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
Antibody first published in:
Yamamoto et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma (Yamamoto, 2010) Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 March 2010, Vol.28(9), pp.1591-8 PMID:20177026
Note on publication: Imai et al (1999) describes the use of a mouse anti-CCR4 antibody to isolate CCR4+ cells using labelling and FC studies. Yamamoto et al (2010) descibes the successful testing of the humanized, defucosylated form of this anti-CCR4 antibody in a phase I trial.
Western Blot using anti-CCR4 antibody KW-0761 (Mogamulizumab) (Ab00726) Human brain cerebellum (A) and human heart (B) lysates (35µg protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 (Ab00726-23.0) at 2 µg/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.